_PRIVATE_LIMITED.webp)
Pharmtak Ophthalmics (I) Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 05-01-2025
- Paid Up Capital ₹ 1.40 M
as on 05-01-2025
- Company Age 28 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.44 Cr
as on 05-01-2025
- Satisfied Charges ₹ 8.50 Cr
as on 05-01-2025
- Revenue 18.11%
(FY 2023)
- Profit 10.86%
(FY 2023)
- Ebitda 63.99%
(FY 2023)
- Net Worth 10.73%
(FY 2023)
- Total Assets -1.27%
(FY 2023)
About Pharmtak Ophthalmics (I)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.40 M.
The company currently has active open charges totaling ₹6.44 Cr. The company has closed loans amounting to ₹8.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bharat Agarwal, Gaurav Agarwal, and Abeer Agarwal serve as directors at the Company.
- CIN/LLPIN
U85110UP1996PTC020504
- Company No.
020504
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Aug 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Agra, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Pharmtak Ophthalmics (I) Private Limited offer?
Pharmtak Ophthalmics (I) Private Limited offers a wide range of products and services, including Diagnostic Imaging Accessories, Ultrasound Accessories, Nasal Drops, Xylometazoline Nasal Drops, Vitamin Tablets & Capsules, Pharmaceutical Capsules, Softgel Capsules, Eye Care Medicines, Eye Drops.
Who are the key members and board of directors at Pharmtak Ophthalmics (I)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bharat Agarwal  | Director | 16-Aug-1996 | Current |
| Gaurav Agarwal | Director | 31-May-2007 | Current |
| Abeer Agarwal | Director | 09-Jun-2023 | Current |
Financial Performance of Pharmtak Ophthalmics (I).
Pharmtak Ophthalmics (I) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.11% increase. The company also saw a substantial improvement in profitability, with a 10.86% increase in profit. The company's net worth Soared by an impressive increase of 10.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmtak Ophthalmics (I)?
In 2023, Pharmtak Ophthalmics (I) had a public holding of 4.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 28 Mar 2012 | ₹6.40 Cr | Open |
State Bank Of India Creation Date: 08 May 2001 | ₹0.40 M | Open |
Others Creation Date: 24 Jul 2020 | ₹7.00 Cr | Satisfied |
How Many Employees Work at Pharmtak Ophthalmics (I)?
Unlock and access historical data on people associated with Pharmtak Ophthalmics (I), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmtak Ophthalmics (I), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmtak Ophthalmics (I)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
